Effects of Folic Acid and Vitamin B12 Supplementation on Granulosa Cells of the Dominant Follicle of Dairy Cows.

Abstract Objectives To investigate the possible effects of the intervention with folic acid and vitamin B12 supplementation on fracture and cardiovascular disease risk: 5–7 years after the end of the intervention period of 2–3 years. Methods Extended follow-up of B-PROOF trial, a multi-center, double-blind randomized placebo-controlled trial designed to assess the effect of 2–3 years daily supplementation with folic acid (400 µg) and vitamin-B12 (500 µg) versus placebo on fracture incidence. Fracture and cardiovascular outcomes were assessed by follow-up questionnaire. Fracture incidence (and a part of cardiovascular disease incidence) was verified by general practitioners (GPs). Results A total of 1298 individuals participated in the second follow-up round. Median age at baseline was 71.0 years [68.0–76.0] for both groups (n = 662 in the treatment group and n = 636 in the placebo group). No effect of the intervention on first osteoporotic fracture and other fracture risk after a follow up of 5–7 years was observed (HR: 0.99, 95% CI: 0.62; 1.59 and HR: 0.77; 95% CI: 0.50; 1.19, respectively) and also not for cardiovascular- or cerebrovascular disease (OR: 1.14; 95%CI: 0.74–1.74 and OR: 1.01; 95%CI: 0.76–1.33, respectively). Significant interaction for total homocysteine level was observed for osteoporotic- and any fracture (P = 0.10 and 0.06 resp.), which indicated a significantly lower risk of fracture in the intervention group with higher total homocysteine level. Conclusions This study does not support a prolonged effect of supplementation of folic acid and vitamin B12 on fracture risk, or on cardiovascular disease in older individuals with elevated homocysteine concentration. However, B-vitamin supplementation may be beneficial in reducing fractures in individuals with higher total homocysteine levels. Funding Sources The initial B-PROOF study has received funding so far by The Netherlands Organization for Health Research and Development (ZonMw), the Hague; unrestricted grant from NZO (Dutch Dairy Association), Zoetermeer; Orthica, Almere; NCHA (Netherlands Consortium Healthy Ageing) Leiden/Rotterdam; Ministry of Economic Affairs, Agriculture and Innovationn, the Hague; Wageningen University, Wageningen; VUmc, Amsterdam; Erasmus Medical Center, Rotterdam. Supporting Tables, Images and/or Graphs

Download Full-text

Response of early lactation dairy cows to the inclusion of the liver technology product ABN-LiFT in the total mixed ration

Proceedings of the British Society of Animal Science ◽

10.1017/s175275620000853x ◽

2002 ◽

Vol 2002 ◽

pp. 197-197

Author(s):

C A Middlemass ◽

C M Minter ◽

M Marsden

Keyword(s):

Folic Acid ◽

Vitamin B12 ◽

Dairy Cows ◽

Energy Requirement ◽

High Energy ◽

Early Lactation ◽

Dry Period ◽

Total Mixed Ration ◽

Methyl Group ◽

Technology Product

Through the dry period to early lactation the cow goes through a dramatic change in her metabolism. To supply the high energy requirement in early lactation fat supply from the diet and body mobilisation increases substantially. As a result, the liver accumulates fat, the rate of detoxification slows down, ammonia accumulates and there’s a reduced supply of fat, glucose and protein to the udder. This trial was designed to evaluate the response of dairy cows to product called ABN-LiFT a proprietary mixture of B-group vitamins and methyl group donors (rumen protected choline, niacin, vitamin B12, biotin, folic acid and thiamine) designed to reduce the accumulation of triglycerides in the liver and accelerate VLDL export.

Download Full-text